BAL0891, a first-in-class dual TTK/PLK1 inhibitor, activates the cGAS/STING pathway and induces a senescence-associated secretory phenotype (SASP), resulting in increased PD-L1 expression and pro-inflammatory cytokine production in cancer cells.
Dysregulation of cell cycle checkpoints in cancer cells drives uncontrolled proliferation and tumor progression.
Many approvals of advanced drugs, such as Antibody-Drug Conjugates (ADCs) or immunotherapies, have not provided significant treatment benefits for patients with metastatic gastric cancer (GC).
Drug-induced liver injury (DILI) represents a significant challenge in both medical practice and drug development.
Numerous diseases, including age-related macular degeneration (AMD), arise from the blood-retinal barrier and blood vessel abnormalities in the eye; unfortunately, there is a lack of reliable in vitro models for their systematic study.
Despite significant advancements in scientific and diagnostic technologies, clinical trials for cancer often fail due to a lack of efficacy.
Numerous diseases, including AMD (age-related macular degeneration), arise from the blood-retinal barrier and blood vessel abnormalities in the eye; unfortunately, there is a lack of reliable in-vitro models for their systematic study.
Drug-induced liver injury (DILI) is a major failure mode in pharmaceutical development.